Diligence memo · auto-generated · as of July 2, 2026

SynapDx Corp.

SynapDx Corp. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

SynapDx Corp. operates in Biotechnology, based in Lexington.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

SynapDx Corp. has raised $25M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $15M on 2013-07-18.

Most recent recorded round closed around 2013-07-18.

Valuation (modeled)modeled

Provath models SynapDx Corp. at approximately $609M (range $31M–$2.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.85× the median modeled value of Series B Biotechnology companies in 2013–2015 (77 peers) — value vs value, same stage and era. Within the normal band (85% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 38 months.

Last raise 13.0 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.6× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 71% of Biotechnology peers (4293 compared).

Modeled value ranks above 85% of those peers.

Closest niche peers: BioAtla,LLC, Scholar Rock LLC, Oligasis, LLC, Alector LLC, Gelesis Inc.

Peoplefiled

8 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.